nach oben

World Journal of Urology

Erschienen in:

01.08.2003 | Free Paper

The prognostic value of p53 and DNA ploidy following radical prostatectomy

verfasst von: C. Deliveliotis, A. Skolarikos, A. Karayannis, V. Tzelepis, N. Trakas, E. Alargof, V. Protogerou

Erschienen in: World Journal of Urology | Ausgabe 3/2003

Einloggen, um Zugang zu erhalten

Abstract

This study assesses the correlation of p53 immunoreactivity and DNA ploidy status with biochemical recurrence after radical prostatectomy. p53 protein expression and DNA ploidy were evaluated on 84 archival paraffin-embedded radical prostatectomy specimens. Patients were divided into two groups: those with low (38/84, 45%) and those with high (46/84, 55%) p53 immunoreactivity. The results were correlated with Gleason score, stage and serum PSA. Kaplan-Meier biochemical recurrence free survival and the Cox hazard-regression model were used for analysis. Multivariate analysis revealed p53, DNA ploidy, Gleason score, PSA and stage to be independent prognostic factors in this order. Kaplan-Meier analysis showed a significant difference in biochemical recurrence when p53 high expression and DNA aneuploidy were combined. The results of this study suggest that stratification for p53 expression and DNA ploidy status can provide additional prognostic information for patients with prostate carcinoma after radical prostatectomy.

Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW (1996) Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 156:1511–1516PubMed

Borre M, Stausbol-gron B, Overgaard J (2000) p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol 164:716–721PubMed

Bostwick D, Grignon D, Hammond M, Amin M, Cohen M, Crawford D, Gospadarovicz M, Kaplan R, Miller D, Montironi R, Pajak T, Pollack A, Srigley J, Yarbro J (2000) Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 995–1000PubMed

Brewster SF, Oxley JD, Trivella M, Abbott C, Gillatt D (1999) Preoperative p53, bcl-2, CD44, and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 161:1238–1243PubMed

Brooks J, Bova G, Ewing C, Piantadosi S, Carter B, Robinson J, Epstein J, Isaacs W (1996) An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 56:3814–3822PubMed

Carroll A, Voeller H, Sugars L, Gelmann E (1993) p53 oncogene mutations in three human prostate cancer cell lines. Prostate 23:123–134PubMed

Hawkins CA, Bergstralh EJ, Lieber MM, Zinke H (1995) Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical prostatectomy. Urology 46: 356–364CrossRefPubMed

Kallakury BV, Figge J, Ross JS, Fisher H, Figge H, Jennings T (1994) Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Hum Pathol 25:92–97PubMed

Krupski T, Petroni G, Frierson H, Theodoresku D (2000) Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology 55:743–749CrossRefPubMed

10.

Kuczyk MA, Serth J, Bokemeyer C, Machtens S, Minssen A, Bathke W, Hartmann J, Jonas U (1998) The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. Eur J Cancer 34:679–686CrossRefPubMed

11.

Leibovich BC, Cheng L, Weaver AL, Myers RP, Botwick D (2000) Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer. J Urol 163:1756–1760PubMed

12.

Lerner SE, Blute ML, Zincke H (1996) Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol 14(4):12–20PubMed

13.

Martinez Jaboloyas J, Ruiz Cerda J, Sanz Chinesta S, Jimenez A, Hernandez M, Jimenez Cruz J (2001) Prognostic value of DNA ploidy in prostatic cancer. Actas Urol Esp 25: 283–290PubMed

14.

Mora LB, Moscinski LC, Diaz JI, Blair P, Cantor AB, Pow-Sang JM (1999) Stage B prostate cancer: correlation of DNA ploidy analysis with histological and clinical parameters. Cancer Control 6:587–591PubMed

15.

Murphy GP, Mettlin C, Menck H, Winchester DP, Davidson AM (1994) National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission of Cancer. J Urol 152:1817–1819PubMed

16.

Oxley JD, Winkler MH, Parry K, Brewster SF, Abbott C, Gillatt DA (2002) p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy. BJU Int 89:27–32CrossRefPubMed

17.

Quinn DI, Henshall SM, Head DR, Golovsky D Wilson D, Brenner P, Turner J, Delprado W, Finlayson J, Stricker P, Grygiel J, Sutherland R (2000) Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatetomy. Cancer Res 60:1585–1594PubMed

18.

Stackhouse GB, Sesterhenn IA, Bauer JJ, Mostofi FK, Connelly RR, Srivastava SK, Moul JW (1999) p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 162:2040–2045PubMed

19.

Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF (1997) p53, bcl-2, and retinoblastoma proteins as long term prognostic markers in localized carcinoma of the prostate. J Urol 158:131–137PubMed

20.

Uzoaru I, Rubenstein M, Mirochnik Y, Slobodskoy L, Shaw M, Guinan P (1998) An evaluation of the markers p53 and ki-67 for their predictive value in prostate cancer. J Surg Oncol 67:33–37CrossRefPubMed

21.

Vesalainen S, Lipponen P, Nordling S, Talja M, Syrjanen K (1995) Results of the primary treatment in T1-3M0 prostatic adenocarcinoma are dependent on tumour biology. Anticancer Res 15:569–573PubMed

Titel: The prognostic value of p53 and DNA ploidy following radical prostatectomy
verfasst von: C. Deliveliotis
A. Skolarikos
A. Karayannis
V. Tzelepis
N. Trakas
E. Alargof
V. Protogerou
Publikationsdatum: 01.08.2003
Verlag: Springer-Verlag
Erschienen in: World Journal of Urology / Ausgabe 3/2003
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-003-0345-0

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The prognostic value of p53 and DNA ploidy following radical prostatectomy

Abstract

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Fehlerkultur in der Medizin – Offenheit zählt!

Update Urologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2003

Experience with different questionnaires in the management of patients with CP/CPPS: GPSS, IPSS and NIH-CPSI

Da Vinci robot assisted Anderson-Hynes dismembered pyeloplasty: technique and 1 year follow-up

Apical dissection during radical retropubic prostatectomy without ligature

Unilateral transurethral incision for primary bladder neck obstruction: symptom relief and fertility preservation

A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life

Editorial comment on Schneider et al., Experience with different questionnaires in the management of patients with CP/CPPS: GPSS, IPSS and NIH-CPSI

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Fehlerkultur in der Medizin – Offenheit zählt!

Update Urologie